Overexpressed CD39 mitigates sepsis‑induced kidney epithelial cell injury via suppressing the activation of NLR family pyrin domain containing 3

Yang,Meixia; Lu,Linxin; Kang,Zhiqin; Ma,Tianlong; Wang,Yu

doi:10.3892/ijmm.2019.4349

Overexpressed CD39 mitigates sepsis‑induced kidney epithelial cell injury via suppressing the activation of NLR family pyrin domain containing 3

Authors:
- Meixia Yang
- Linxin Lu
- Zhiqin Kang
- Tianlong Ma
- Yu Wang
View Affiliations

Affiliations: Department of Emergency, Shanxi Dayi Hospital, Taiyuan, Shanxi 030032, P.R. China
Published online on: September 23, 2019 https://doi.org/10.3892/ijmm.2019.4349
Pages: 1707-1718
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Unfettered inflammation is a leading cause of multiple organ failures in sepsis. The anti‑inflammatory role of cluster of differentiation (CD)39 has been previously reported. The present study aimed to investigate the role of unfettered inflammation in sepsis‑induced acute kidney injury (AKI). Lipopolysaccharide (LPS) was introduced to construct a sepsis mouse model. Kidney function and pathological changes in mice were measured at 12, 24 and 48 h. CD39 overexpression and inhibition vectors were transfected into renal tubular epithelial (HK‑2) cells, followed by LPS treatment (10 µg/ml), and the cell viability changes at 24 h after treatment were assessed and the expression of NLR family pyrin domain containing 3 (NLRP3), cleaved caspase‑1 and CD39 were determined by performing ELISAs. Cell apoptosis and reactive oxygen species (ROS) levels were determined by flow cytometry. It was found that after LPS administration, kidney injury was the most serious at 24 h in mice. CD39 overexpression could suppress the upregulation of pro‑inflammatory cytokines induced by LPS treatment. In addition, the cell apoptosis and ROS level exhibited an obvious decrease, while cell viability increased. The NLRP3 expression and activity also showed a great inhibition in CD39‑overexpressed cells. By contrast to CD39 overexpression, CD39 inhibition promoted the activation of the NLRP3 inflammasome. These data indicate the protective role of CD39 in LPS‑induced renal tubular epithelial cell damage through inhibiting NLRP3 inflammasome activation and that CD39 might be a potential therapeutic target in sepsis‑induced AKI.

View Figures

View References

1	Angus DC and van der Poll T: Severe sepsis and septic shock. N Engl J Med. 369:20632013. View Article : Google Scholar : PubMed/NCBI
2	Aziz M, Jacob A, Yang WL, Matsuda A and Wang P: Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol. 93:329–342. 2013. View Article : Google Scholar :
3	Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, et al: Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study. Intensive Care Med. 41:1411–1423. 2015. View Article : Google Scholar : PubMed/NCBI
4	Khwaja A: KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 120:pp. c179–c184. 2012, PubMed/NCBI
5	Alobaidi R, Basu RK, Goldstein SL and Bagshaw SM: Sepsis-associated acute kidney injury. Semin Nephrol. 35:2–11. 2015. View Article : Google Scholar : PubMed/NCBI
6	Cruz DN, Bolgan I, Perazella MA, Bonello M, de Cal M, Corradi V, Polanco N, Ocampo C, Nalesso F, Piccinni P, et al: North east italian prospective hospital renal outcome survey on acute kidney injury (NEiPHROS-AKI): Targeting the problem with the RIFLE criteria. Clin J Am Soc Nephrol. 2:418–425. 2007. View Article : Google Scholar : PubMed/NCBI
7	Mayeux PR and MacMillan-Crow LA: Pharmacological targets in the renal peritubular microenvironment: Implications for therapy for sepsis-induced acute kidney injury. Pharmacol Ther. 134:139–155. 2012. View Article : Google Scholar : PubMed/NCBI
8	Langenberg C, Bellomo R, May C, Wan L, Egi M and Morgera S: Renal blood flow in sepsis. Crit Care. 9:R363–R374. 2005. View Article : Google Scholar : PubMed/NCBI
9	Schrier RW and Wang W: Acute renal failure and sepsis. N Engl J Med. 351:159–169. 2004. View Article : Google Scholar : PubMed/NCBI
10	Takasu O, Gaut JP, Watanabe E, To K, Fagley RE, Sato B, Jarman S, Efimov IR, Janks DL, Srivastava A, et al: Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med. 187:509–517. 2013. View Article : Google Scholar : PubMed/NCBI
11	Dong W, Li Z, Chen Y, Zhang L, Ye Z, Liang H, Li R, Xu L, Zhang B, Liu S, et al: Necrostatin-1 attenuates sepsis-associated acute kidney injury by promoting autophagosome elimination in renal tubular epithelial cells. Mol Med Rep. 17:3194–3199. 2018.
12	De Backer D, Creteur J, Preiser JC, Dubois MJ and Vincent JL: Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 166:98–104. 2002. View Article : Google Scholar : PubMed/NCBI
13	Cen C, Aziz M, Yang WL, Zhou M, Nicastro JM, Coppa GF and Wang P: Milk fat globule-epidermal growth factor-factor VIII attenuates sepsis-induced acute kidney injury. J Surg Res. 213:281–289. 2017. View Article : Google Scholar : PubMed/NCBI
14	Mir SM, Ravuri HG, Pradhan RK, Narra S, Kumar JM, Kuncha M, Kanjilal S and Sistla R: Ferulic acid protects lipopolysaccha-ride-induced acute kidney injury by suppressing inflammatory events and upregulating antioxidant defenses in Balb/c mice. Biomed Pharmacother. 100:304–315. 2018. View Article : Google Scholar : PubMed/NCBI
15	Eltzschig HK, Sitkovsky MV and Robson SC: Purinergic signaling during inflammation. N Engl J Med. 367:2322–2333. 2012. View Article : Google Scholar : PubMed/NCBI
16	Yan J, Li Y, Yang H, Zhang L, Yang B, Wang M and Li Q: Interleukin-17A participates in podocyte injury by inducing IL-1β secretion through ROS-NLRP3 inflammasome-caspase-1 pathway. Scand J Immunol. 87:pp. e126452018, View Article : Google Scholar
17	Yao ST, Cao F, Chen JL, Chen W, Fan RM, Li G, Zeng YC, Jiao S, Xia XP, Han C and Ran QS: NLRP3 is required for complement-mediated caspase-1 and IL-1beta activation in ICH. J Mol Neurosci. 61:385–395. 2017. View Article : Google Scholar
18	Pérez-Cabeza de Vaca R, Dominguez-López M, Guerrero-Celis N, Rodriguez-Aguilera JR and Chagoya de Sánchez V: Inflammation is regulated by the adenosine derivative molecule, IFC-305, during reversion of cirrhosis in a CCl₄ rat model. Int Immunopharmacol. 54:12–23. 2018. View Article : Google Scholar
19	Xu Y, Wang Y, Yan S, Yang Q, Zhou Y, Zeng X, Liu Z, An X, Toque HA, Dong Z, et al: Regulation of endothelial intracellular adenosine via adenosine kinase epigenetically modulates vascular inflammation. Nat Commun. 8:9432017. View Article : Google Scholar : PubMed/NCBI
20	Savio LEB, de Andrade Mello P, Figliuolo VR, de Avelar Almeida TF, Santana PT, Oliveira SDS, Silva CLM, Feldbrügge L, Csizmadia E, Minshall RD, et al: CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury. J Hepatol. 67:716–726. 2017. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
22	Tabas I and Glass CK: Anti-inflammatory therapy in chronic disease: Challenges and opportunities. Science. 339:166–172. 2013. View Article : Google Scholar : PubMed/NCBI
23	Dinarello CA, Simon A and van der Meer JW: Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 11:633–652. 2012. View Article : Google Scholar : PubMed/NCBI
24	Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, Wu Y, Mayo L, Ben-Hamo R, Efroni S, et al: IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol. 14:1054–1063. 2013. View Article : Google Scholar : PubMed/NCBI
25	Jo EK, Kim JK, Shin DM and Sasakawa C: Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 13:148–159. 2016. View Article : Google Scholar :
26	Zhong Z, Sanchez-Lopez E and Karin M: Autophagy, NLRP3 inflammasome and auto-inflammatory/immune diseases. Clin Exp Rheumatol. 34(4 Suppl 98): pp. S12–S16. 2016
27	Mao K, Chen S, Chen M, Ma Y, Wang Y, Huang B, He Z, Zeng Y, Hu Y, Sun S, et al: Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Cell Res. 23:201–212. 2013. View Article : Google Scholar : PubMed/NCBI
28	Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, et al: NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 493:674–678. 2013. View Article : Google Scholar
29	Stearnskurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S and Remick DG: The pathogenesis of sepsis. Annu Rev Pathol. 6:19–48. 2011. View Article : Google Scholar
30	Csóka B, Németh ZH, Törő G, Koscsó B, Kókai E, Robson SC, Enjyoji K, Rolandelli RH, Erdélyi K, Pacher P and Haskó G: CD39 improves survival in microbial sepsis by attenuating systemic inflammation. FASEB J. 29:25–36. 2015. View Article : Google Scholar :
31	Bhat M, Romagnuolo J, da Silveira E, Reinhold C, Valois E, Martel M, Barkun JS and Barkun AN: Randomised clinical trial: MRCP-first vs. ERCP-first approach in patients with suspected biliary obstruction due to bile duct stones. Aliment Pharmacol Ther. 38:1045–1053. 2013. View Article : Google Scholar : PubMed/NCBI
32	Li F, Xu M, Wang M, Wang L, Wang H, Zhang H, Chen Y, Gong J, Zhang JJ, Adcock IM, et al: Roles of mitochondrial ROS and NLRP3 inflammasome in multiple ozone-induced lung inflammation and emphysema. Respir Res. 19:2302018. View Article : Google Scholar : PubMed/NCBI
33	Yu X, Zhao Q, Zhang X and Zhang H, Liu Y, Wu X, Li M, Li X, Zhang J, Ruan X and Zhang H: Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation. Oncotarget. 8:67300–67314. 2017.PubMed/NCBI
34	Knowles JR: Enzyme-catalyzed phosphoryl transfer reactions. Annu Rev Biochem. 49:877–919. 1980. View Article : Google Scholar : PubMed/NCBI
35	Morandini AC, Savio LE and Coutinho-Silva R: The role of P2X7 receptor in infectious inflammatory diseases and the influence of ectonucleotidases. Biomed J. 37:169–177. 2014. View Article : Google Scholar : PubMed/NCBI
36	Robson SC, Sévigny J and Zimmermann H: The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance. Purinergic Signal. 2:409–430. 2006. View Article : Google Scholar